相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Using EGFR amplification to stratify recurrent glioblastoma treated with immune checkpoint inhibitors
Joshua S. S. Friedman et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2023)
Tumor-Derived Pericytes Driven by EGFR Mutations Govern the Vascular and Immune Microenvironment of Gliomas
Berta Segura-Collar et al.
CANCER RESEARCH (2021)
Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial
Assuntina G. Sacco et al.
LANCET ONCOLOGY (2021)
Therapeutic Efficacy of GC1118, a Novel Anti-EGFR Antibody, against Glioblastoma with High EGFR Amplification in Patient-Derived Xenografts
Kyoungmin Lee et al.
CANCERS (2020)
Comparison of Biomarker Assays for EGFR: Implications for Precision Medicine in Patients with Glioblastoma
Andrew B. Lassman et al.
CLINICAL CANCER RESEARCH (2019)
GC1118, a novel anti-EGFR antibody, has potent KRAS mutation-independent antitumor activity compared with cetuximab in gastric cancer
Ji Eun Park et al.
GASTRIC CANCER (2019)
Determining cell type abundance and expression from bulk tissues with digital cytometry
Aaron M. Newman et al.
NATURE BIOTECHNOLOGY (2019)
A First-in-Human Phase I Study of GC1118, a Novel Anti-Epidermal Growth Factor Receptor Antibody, in Patients with Advanced Solid Tumors
Do-Youn Oh et al.
ONCOLOGIST (2019)
Promising Therapeutic Efficacy of GC1118, an Anti-EGFR Antibody, against KRAS Mutation-Driven Colorectal Cancer Patient-Derived Xenografts
Hye Won Lee et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Longitudinal molecular trajectories of diffuse glioma in adults
Floris P. Barthel et al.
NATURE (2019)
ACTR-21. A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 TRIAL OF DEPATUXIZUMAB MAFODOTIN (ABT-414) IN EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) AMPLIFIED (AMP) NEWLY DIAGNOSED GLIOBLASTOMA (nGBM)
Andrew Lassman et al.
NEURO-ONCOLOGY (2019)
Gamma-delta (γδ) T cells: friend or foe in cancer development?
Yijing Zhao et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2018)
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer
J. -C. Soria et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial
Michael Weller et al.
LANCET ONCOLOGY (2017)
GC1118, an Anti-EGFR Antibody with a Distinct Binding Epitope and Superior Inhibitory Activity against High-Affinity EGFR Ligands
Yangmi Lim et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Clonal evolution of glioblastoma under therapy
Jiguang Wang et al.
NATURE GENETICS (2016)
Epidermal growth factor receptor targeting and challenges in glioblastoma
Amy Haseley Thorne et al.
NEURO-ONCOLOGY (2016)
Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma
Kathryn M. Field et al.
NEURO-ONCOLOGY (2015)
Ex Vivo Antibody-Dependent Cellular Cytotoxicity Inducibility Predicts Efficacy of Cetuximab
Rodney J. Taylor et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial
Walter Taal et al.
LANCET ONCOLOGY (2014)
Challenges to targeting epidermal growth factor receptor in glioblastoma: escape mechanisms and combinatorial treatment strategies
Patrick Roth et al.
NEURO-ONCOLOGY (2014)
Bevacizumab for Newly Diagnosed Glioblastoma Reply
Olivier L. Chinot et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Bevacizumab plus Radiotherapy-Temozolomide for Newly Diagnosed Glioblastoma
Olivier L. Chinot et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
The Somatic Genomic Landscape of Glioblastoma
Cameron W. Brennan et al.
CELL (2013)
Phase II Study of Bevacizumab in Combination with Sorafenib in Recurrent Glioblastoma (N0776): A North Central Cancer Treatment Group Trial
Evanthia Galanis et al.
CLINICAL CANCER RESEARCH (2013)
Phase III Randomized Trial Comparing the Efficacy of Cediranib As Monotherapy, and in Combination With Lomustine, Versus Lomustine Alone in Patients With Recurrent Glioblastoma
Tracy T. Batchelor et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Cetuximab-mediated Tumor Regression Depends on Innate and Adaptive Immune Responses
Xuanming Yang et al.
MOLECULAR THERAPY (2013)
Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples
Kristian Cibulskis et al.
NATURE BIOTECHNOLOGY (2013)
Standards of care for treatment of recurrent glioblastoma-are we there yet?
Michael Weller et al.
NEURO-ONCOLOGY (2013)
Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics
Andrea Sottoriva et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Improved survival time trends for glioblastoma using the SEER 17 population-based registries
Matthew Koshy et al.
JOURNAL OF NEURO-ONCOLOGY (2012)
Sequence analysis of mutations and translocations across breast cancer subtypes
Shantanu Banerji et al.
NATURE (2012)
Absolute quantification of somatic DNA alterations in human cancer
Scott L. Carter et al.
NATURE BIOTECHNOLOGY (2012)
Acquired MET expression confers resistance to EGFR inhibition in a mouse model of glioblastoma multiforme
H. J. Jun et al.
ONCOGENE (2012)
Natural killer (NK):dendritic cell (DC) cross talk induced by therapeutic monoclonal antibody triggers tumor antigen-specific T cell immunity
Steve C. Lee et al.
IMMUNOLOGIC RESEARCH (2011)
GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers
Craig H. Mermel et al.
GENOME BIOLOGY (2011)
DEGseq: an R package for identifying differentially expressed genes from RNA-seq data
Likun Wang et al.
BIOINFORMATICS (2010)
Fast and SNP-tolerant detection of complex variants and splicing in short reads
Thomas D. Wu et al.
BIOINFORMATICS (2010)
Phase III Study of Enzastaurin Compared With Lomustine in the Treatment of Recurrent Intracranial Glioblastoma
Wolfgang Wick et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group
Patrick Y. Wen et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma
B. Neyns et al.
ANNALS OF ONCOLOGY (2009)
The Sequence Alignment/Map format and SAMtools
Heng Li et al.
BIOINFORMATICS (2009)
Fast and accurate short read alignment with Burrows-Wheeler transform
Heng Li et al.
BIOINFORMATICS (2009)
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
L. Chin et al.
NATURE (2008)
Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines
Jun Kurai et al.
CLINICAL CANCER RESEARCH (2007)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Sample size tables for exact single-stage phase II designs
RP A'Hern
STATISTICS IN MEDICINE (2001)
分享论文
